×
About 395 results

ALLMedicine™ Alveolar Soft Part Sarcoma Center

Research & Reviews  131 results

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
https://clinicaltrials.gov/ct2/show/NCT01391962

Aug 5th, 2022 - Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS. Little is known with regards to relevan...

PEComa-like Neoplasms Characterized by ASPSCR1-TFE3 Fusion: Another Face of TFE3-relate...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298479
The American Journal of Surgical Pathology; Argani P, Wobker SE et. al.

Jul 19th, 2022 - Identical TFE3-related gene fusions may be found in renal cell carcinoma and mesenchymal neoplasms such as alveolar soft part sarcoma and TFE3-rearranged perivascular epithelioid cell tumor (PEComa). Among mesenchymal neoplasms, the ASPSCR1-TFE3 g...

Significance of immunohistochemistry and FISH of TFE3 in the diagnosis of alveolar soft...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259144
Medicine Huang YY, Yang WR et. al.

Jul 9th, 2022 - Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma harboring an ASPL-TFE3 fusion gene. Herein, we report a case of ASPS associated with brain metastasis. Immunohistochemistry (IHC) for TFE3 antigen expression and fluorescence in situ ...

Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study
https://clinicaltrials.gov/ct2/show/NCT05333458

Jul 6th, 2022 - PRIMARY OBJECTIVE: I. Determine the overall response rate (by Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1) for selinexor in combination with atezolizumab in immune checkpoint inhibitor (ICI)-naive patients with alveolar so...

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma
https://clinicaltrials.gov/ct2/show/NCT03141684

Jun 30th, 2022 - PRIMARY OBJECTIVES: I. Determine the objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 of atezolizumab in patients with advanced alveolar soft part sarcoma (ASPS) in adult subjects >= 18 year...

see more →

Clinicaltrials.gov  15 results

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
https://clinicaltrials.gov/ct2/show/NCT01391962

Aug 5th, 2022 - Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS. Little is known with regards to relevan...

Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study
https://clinicaltrials.gov/ct2/show/NCT05333458

Jul 6th, 2022 - PRIMARY OBJECTIVE: I. Determine the overall response rate (by Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1) for selinexor in combination with atezolizumab in immune checkpoint inhibitor (ICI)-naive patients with alveolar so...

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma
https://clinicaltrials.gov/ct2/show/NCT03141684

Jun 30th, 2022 - PRIMARY OBJECTIVES: I. Determine the objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 of atezolizumab in patients with advanced alveolar soft part sarcoma (ASPS) in adult subjects >= 18 year...

Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
https://clinicaltrials.gov/ct2/show/NCT00942877

Mar 22nd, 2022 - Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS. Little is known with regards to relevan...

see more →

News  12 results

Investigators Express Confidence in a Novel TKI That Targets Rare Sarcomas
https://www.onclive.com/view/investigators-express-confidence-in-a-novel-tki-that-targets-rare-sarcomas

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Anlotinib, a novel tyrosine kinase inhibitor capable of mounting a multipronged attack against oncogenic processes, is being tested in rare soft tissue sarcoma subtypes where patients have limited therapeutic options. ...

NY-ESO-1, MAGE-A4 Among Key Targets in Sarcoma Research
https://www.onclive.com/view/nyeso1-magea4-among-key-targets-in-sarcoma-research

Oct 6th, 2021 - Neeta Somaiah, MD Therapeutic advances in soft tissue sarcoma have occurred across several subtypes, and more research efforts continue to be conducted with novel agents targeting NY-ESO-1 and MAGE-A4, for example, explained Neeta Somaiah, MD. F...

Key Advances in Sarcoma Lead to More Personalized Medicine Efforts
https://www.onclive.com/view/key-advances-in-sarcoma-lead-to-more-personalized-medicine-efforts

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Soft tissue sarcoma treatments have significantly advanced within the past year with new available agents, others in the pipeline, and the continued search for biomarkers to make treatment more personalized for patients...

Chemotherapy Sensitivity in Soft Tissue Sarcoma
https://www.onclive.com/view/chemotherapy-sensitivity-in-soft-tissue-sarcoma

Apr 2nd, 2021 - Transcript:William D. Tap, MD: One of the things I want to get back to is this comment that sarcoma is a chemotherapy-insensitive disease. I’m sure we can talk about, and we will, some diseases that are chemotherapy-insensitive. But what’s your th...

Soft Tissue Sarcoma: Unmet Needs
https://www.onclive.com/view/soft-tissue-sarcoma-unmet-needs

Apr 2nd, 2021 - Transcript: Neeta Somaiah, MD: I think that’s a good transition point to talk about what you think are the biggest unmet needs in patients with sarcoma. Again, I know this is a broad statement, and I’m sure there are unmet needs for patients wi...

see more →